Guardant Health Expands Precision Oncology Offerings

Guardant’s Q2 revenues grew 39% over the year to $92.1 million, ahead of the Street’s forecast by 8.8%. On an adjusted basis, it reported a loss of $0.96 per share, falling below the Street’s estimates of a loss of $0.87 cents per share.